Press Release


Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 05, 2026 10:55 JST
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd.
More info..

Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
May 07, 2025 18:06 JST
Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA).
More info..

Latest Release


More Latest Release >>